Clik here to view.
Cipher signs up Canadian distributor for Tramadol
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela...
View ArticleClik here to view.
Cipher readies regulatory filings for acne product
Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million...
View ArticleClik here to view.
Zacks starts Cipher at outperform
Zacks Investment Research has initiated coverage of Cipher Pharmaceuticals (TSX:DND) with an “outperform” rating and 12-month price target of $2.25. The stock closed at 64 cents on Wednesday. “Based on...
View ArticleClik here to view.
Health Canada accepts Cipher acne filing for review
Health Canada has accepted for review a New Drug Submission by Cipher Pharmaceuticals (TSX: DND) for its CIP-Isotretinoin, a novel, patented formulation of the acne medication isotretinoin. The company...
View ArticleClik here to view.
Cipher partner launches of Durela in Canada
Cipher Pharmaceuticals’ (TSX:DND; OTCBB:CPHMF) partner, Medical Futures, has launched Durela, an extended-release tramadol product, in key markets across Canada, with a dedicated sales force of about...
View ArticleClik here to view.
Cipher posts Q1 profit on 168% revenue gain
Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) achieved a profit of $125,000 in the first quarter this year, compared with a year earlier loss of $1.1 million, as revenue rose 168% to $1.8 million....
View ArticleClik here to view.
Cipher posts strong second quarter results
Cipher Pharmaceuticals (TSX:DND; OTCBB: CPHMF) has posted second quarter profit of $200,000, compared with a year earlier loss of $500,000, on a 124% jump in revenue to $1.6-million. “It was an...
View ArticleClik here to view.
Cipher partner launches Absorica in U.S.
Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne...
View ArticleClik here to view.
Cipher Pharma adopts 5-by-5 mantra for future growth
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. Shawn O’Brien “I want to...
View Article
